-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I29CcOI+fSU9TY7S0nP46sG3FnJKhIFq3Ne5fK/eUIBJhQgjWYlxWpytEz6Yfg8m NtSvF6jsFNop9tF1XjYsIg== 0000950123-99-007666.txt : 19990816 0000950123-99-007666.hdr.sgml : 19990816 ACCESSION NUMBER: 0000950123-99-007666 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990813 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NORTH AMERICAN VACCINE INC CENTRAL INDEX KEY: 0000856573 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980121241 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-49421 FILM NUMBER: 99689779 BUSINESS ADDRESS: STREET 1: 10150 OLD COLUMBIA ROAD CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 4103097100 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOCHEM PHARMA INC CENTRAL INDEX KEY: 0000867202 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: E6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 275 ARMAND-FRAPPIER BLVD CITY: LAVAL QUEBEC STATE: E6 BUSINESS PHONE: 5146811744 MAIL ADDRESS: STREET 1: 275 ARMAND FRAPPIER BLVD CITY: LAVAL QUEBEC STATE: E6 SC 13D/A 1 AMENDMENT #10 TO SCHEDULE 13D 1 Page 1 of 4 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 10)* North American Vaccine, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, No Par Value - -------------------------------------------------------------------------------- (Title of Class of Securities) 657-201-109 - -------------------------------------------------------------------------------- (CUSIP Number) Charles-A. Tessier, Vice-President, Legal Affairs and General Counsel BioChem Pharma Inc., 275 Armand Frappier Boulevard, Laval, Quebec H7V 4A7 Canada - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 11, 1999 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 657-201-109 Page 2 of 4 pages - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON BIOCHEM PHARMA INC. - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Laval, Quebec, Canada - ------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 15,040,704 BENEFICIALLY ---------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING N/A PERSON ---------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 15,040,704 ---------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER N/A - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,040,704 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / N/A - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 41.6% - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 3 Page 3 of 4 Pages This amendment Number 10 amends and supplements the Statement on Schedule 13D (the "Schedule 13D") filed on behalf of BioChem Pharma Inc. ("BioChem"), a publicly-owned Canadian pharmaceutical company incorporated under the laws of Canada, relating to the common stock, no par value per share, of North American Vaccine, Inc. (the "Company"). Capitalized terms used and not defined in this Amendment have the meanings set forth in the Schedule 13D. Item 4 of the Schedule 13D, "Purpose of Transaction", is hereby amended and supplemented to add the following: Item 4. Purpose of Transaction On August 4, 1999, BioChem signed an engagement letter which appointed Salomon Smith Barney Canada Inc. as its financial advisor in connection with a potential transaction with respect to the Company. Such potential transaction could include the sale of all or a portion of the securities issued by the Company which are currently held by BioChem, the purchase of all or a portion of the outstanding equity securities issued by the Company which are not currently held by BioChem or other strategic transactions involving the Company. On August 11, 1999, BioChem and the Company entered into a confidentiality agreement (the "Confidentiality Agreement") in order to gain access to information in the possession of the Company which BioChem desires to evaluate in order to determine its future plans with respect to its holdings of securities issued by the Company. Under the terms of the Confidentiality Agreement, BioChem has agreed to hold confidential all information received from the Company and to refrain from engaging in certain actions. BioChem is currently considering a number of plans and proposals which may result in one or more actions described in subparagraphs (a) through (j) of Schedule 13D. BioChem reserves the right to determine in the future whether to pursue any plans or proposals of the type specified above. 4 Page 4 of 4 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BIOCHEM PHARMA INC. By: /s/ Charles-A. Tessier ----------------------------- Charles-A. Tessier Vice-President, Legal Affairs and General Counsel Dated: August 12, 1999 -----END PRIVACY-ENHANCED MESSAGE-----